Last $3.48 USD
Change Today +0.06 / 1.75%
Volume 98.4K
CYCC On Other Exchanges
Symbol
Exchange
Frankfurt
As of 3:40 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Snapshot

Open
$3.42
Previous Close
$3.42
Day High
$3.53
Day Low
$3.31
52 Week High
09/20/13 - $5.50
52 Week Low
08/14/13 - $2.75
Market Cap
69.0M
Average Volume 10 Days
193.0K
EPS TTM
$-1.59
Shares Outstanding
19.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (CYCC)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (CYCC) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (CYCC) Details

Cyclacel Pharmaceuticals, Inc., a development-stage biopharmaceutical company, develops and commercializes mechanism-targeted drugs to treat human cancers and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue that interferes with DNA synthesis and repair by causing single-strand DNA breaks that could induce arrest of the cell division cycle at the G2/M checkpoint; and seliciclib, an orally-available 2nd generation CDK inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2/E, CDK2/A, CDK7, and CDK9 that are central to the process of cell division and cell cycle control. Its other oncology development programs comprise CYC065, an orally-available 2nd generation CDK-2, -5, -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; and Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/26/14
Founded in 1992

cyclacel pharmaceuticals inc (CYCC) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $713.4K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $463.1K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $442.4K
Compensation as of Fiscal Year 2013.

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for Fourth Quarter and Full Year Ended Dec. 31, 2013

Cyclacel Pharmaceuticals, Inc. announced unaudited consolidated earnings results for fourth quarter and full year ended Dec. 31, 2013. For the quarter, the company reported total revenues of $5,000, operating loss of $4,654,000, loss from continuing operations before taxes of $5,067,000, net loss from continuing operations of $4,430,000 or $0.55 per basic and diluted share, net loss applicable to common shareholders of $4,946,000 or $0.59 per basic and diluted share compared to the total revenues of $299,000, operating loss of $3,974,000, loss from continuing operations before taxes of $4,026,000, net loss from continuing operations of $3,574,000 or $0.19 per basic and diluted share, net loss applicable to common shareholders of $3,609,000 or $0.19 per basic and diluted share for the same quarter a year ago. For the year, the company reported total revenues of $69,000, operating loss of $15,103,000, loss from continuing operations before taxes of $15,107,000, net loss from continuing operations of $13,756,000 or $1.75 per basic and diluted share, net loss applicable to common shareholders of $13,914,000 or $1.68 per basic and diluted share compared to the total revenues of $1,084,000, operating loss of $17,974,000, loss from continuing operations before taxes of $11,880,000, net loss from continuing operations of $10,210,000 or $1.29 per basic and diluted share, net loss applicable to common shareholders of $19,478,000 or $1.28 per basic and diluted share for the previous year.

Cyclacel Pharmaceuticals, Inc. Declares Dividend on Convertible Exchangeable Preferred Stock, Payable on May 1, 2014

On March 17, 2014, the Board of Cyclacel Pharmaceuticals, Inc. declared a quarterly cash dividend in the amount of $0.15 per share on the company's 6% Convertible Exchangeable Preferred Stock. The cash dividend will be payable on May 1, 2014 to the holders of record of the Preferred Stock as of the close of business on April 18, 2014.

Cyclacel Pharmaceuticals, Inc. to Report Q4, 2013 Results on Mar 25, 2014

Cyclacel Pharmaceuticals, Inc. announced that they will report Q4, 2013 results at 4:30 PM, Eastern Daylight on Mar 25, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $3.48 USD +0.06

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies
 

Industry Analysis

CYCC

Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 60.1x
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 42.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.